813 related articles for article (PubMed ID: 29576375)
1. Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.
Arce Vargas F; Furness AJS; Litchfield K; Joshi K; Rosenthal R; Ghorani E; Solomon I; Lesko MH; Ruef N; Roddie C; Henry JY; Spain L; Ben Aissa A; Georgiou A; Wong YNS; Smith M; Strauss D; Hayes A; Nicol D; O'Brien T; Mårtensson L; Ljungars A; Teige I; Frendéus B; ; ; ; Pule M; Marafioti T; Gore M; Larkin J; Turajlic S; Swanton C; Peggs KS; Quezada SA
Cancer Cell; 2018 Apr; 33(4):649-663.e4. PubMed ID: 29576375
[TBL] [Abstract][Full Text] [Related]
2. Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3
Sharma A; Subudhi SK; Blando J; Scutti J; Vence L; Wargo J; Allison JP; Ribas A; Sharma P
Clin Cancer Res; 2019 Feb; 25(4):1233-1238. PubMed ID: 30054281
[TBL] [Abstract][Full Text] [Related]
3. Anti-CTLA-4 Activates Intratumoral NK Cells and Combined with IL15/IL15Rα Complexes Enhances Tumor Control.
Sanseviero E; O'Brien EM; Karras JR; Shabaneh TB; Aksoy BA; Xu W; Zheng C; Yin X; Xu X; Karakousis GC; Amaravadi RK; Nam B; Turk MJ; Hammerbacher J; Rubinstein MP; Schuchter LM; Mitchell TC; Liu Q; Stone EL
Cancer Immunol Res; 2019 Aug; 7(8):1371-1380. PubMed ID: 31239316
[TBL] [Abstract][Full Text] [Related]
4. The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production.
Laurent S; Queirolo P; Boero S; Salvi S; Piccioli P; Boccardo S; Minghelli S; Morabito A; Fontana V; Pietra G; Carrega P; Ferrari N; Tosetti F; Chang LJ; Mingari MC; Ferlazzo G; Poggi A; Pistillo MP
J Transl Med; 2013 May; 11():108. PubMed ID: 23634660
[TBL] [Abstract][Full Text] [Related]
5. Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody.
Ha D; Tanaka A; Kibayashi T; Tanemura A; Sugiyama D; Wing JB; Lim EL; Teng KWW; Adeegbe D; Newell EW; Katayama I; Nishikawa H; Sakaguchi S
Proc Natl Acad Sci U S A; 2019 Jan; 116(2):609-618. PubMed ID: 30587582
[TBL] [Abstract][Full Text] [Related]
6. Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer.
Schofield DJ; Percival-Alwyn J; Rytelewski M; Hood J; Rothstein R; Wetzel L; McGlinchey K; Adjei G; Watkins A; Machiesky L; Chen W; Andrews J; Groves M; Morrow M; Stewart RA; Leinster A; Wilkinson RW; Hammond SA; Luheshi N; Dobson C; Oberst M
MAbs; 2021; 13(1):1857100. PubMed ID: 33397194
[TBL] [Abstract][Full Text] [Related]
7. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.
Du X; Tang F; Liu M; Su J; Zhang Y; Wu W; Devenport M; Lazarski CA; Zhang P; Wang X; Ye P; Wang C; Hwang E; Zhu T; Xu T; Zheng P; Liu Y
Cell Res; 2018 Apr; 28(4):416-432. PubMed ID: 29472691
[TBL] [Abstract][Full Text] [Related]
8. Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy.
Sato Y; Casson CN; Matsuda A; Kim JI; Shi JQ; Iwasaki S; Chen S; Modrell B; Chan C; Tavares D; Austen D; Ida K; Tayber O; Hein P; Comeau R; Lin Y; Shaw MH
Cancer Immunol Immunother; 2022 Oct; 71(10):2421-2431. PubMed ID: 35237846
[TBL] [Abstract][Full Text] [Related]
9. FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment.
Knorr DA; Blanchard L; Leidner RS; Jensen SM; Meng R; Jones A; Ballesteros-Merino C; Bell RB; Baez M; Marino A; Sprott D; Bifulco CB; Piening B; Dahan R; Osorio JC; Fox BA; Ravetch JV
Cancer Immunol Res; 2024 Mar; 12(3):322-333. PubMed ID: 38147316
[TBL] [Abstract][Full Text] [Related]
10. Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients.
Romano E; Kusio-Kobialka M; Foukas PG; Baumgaertner P; Meyer C; Ballabeni P; Michielin O; Weide B; Romero P; Speiser DE
Proc Natl Acad Sci U S A; 2015 May; 112(19):6140-5. PubMed ID: 25918390
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology.
Selby MJ; Engelhardt JJ; Johnston RJ; Lu LS; Han M; Thudium K; Yao D; Quigley M; Valle J; Wang C; Chen B; Cardarelli PM; Blanset D; Korman AJ
PLoS One; 2016; 11(9):e0161779. PubMed ID: 27610613
[TBL] [Abstract][Full Text] [Related]
12. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Simpson TR; Li F; Montalvo-Ortiz W; Sepulveda MA; Bergerhoff K; Arce F; Roddie C; Henry JY; Yagita H; Wolchok JD; Peggs KS; Ravetch JV; Allison JP; Quezada SA
J Exp Med; 2013 Aug; 210(9):1695-710. PubMed ID: 23897981
[TBL] [Abstract][Full Text] [Related]
13. Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8
Semmrich M; Marchand JB; Fend L; Rehn M; Remy C; Holmkvist P; Silvestre N; Svensson C; Kleinpeter P; Deforges J; Junghus F; Cleary KL; Bodén M; Mårtensson L; Foloppe J; Teige I; Quéméneur E; Frendéus B
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35058324
[TBL] [Abstract][Full Text] [Related]
14. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.
Gide TN; Quek C; Menzies AM; Tasker AT; Shang P; Holst J; Madore J; Lim SY; Velickovic R; Wongchenko M; Yan Y; Lo S; Carlino MS; Guminski A; Saw RPM; Pang A; McGuire HM; Palendira U; Thompson JF; Rizos H; Silva IPD; Batten M; Scolyer RA; Long GV; Wilmott JS
Cancer Cell; 2019 Feb; 35(2):238-255.e6. PubMed ID: 30753825
[TBL] [Abstract][Full Text] [Related]
15. Genetic basis for clinical response to CTLA-4 blockade in melanoma.
Snyder A; Makarov V; Merghoub T; Yuan J; Zaretsky JM; Desrichard A; Walsh LA; Postow MA; Wong P; Ho TS; Hollmann TJ; Bruggeman C; Kannan K; Li Y; Elipenahli C; Liu C; Harbison CT; Wang L; Ribas A; Wolchok JD; Chan TA
N Engl J Med; 2014 Dec; 371(23):2189-2199. PubMed ID: 25409260
[TBL] [Abstract][Full Text] [Related]
16. Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma.
Bjoern J; Lyngaa R; Andersen R; Hölmich LR; Hadrup SR; Donia M; Svane IM
Oncotarget; 2017 Apr; 8(16):27062-27074. PubMed ID: 28423678
[TBL] [Abstract][Full Text] [Related]
17. Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?
Ménard C; Ghiringhelli F; Roux S; Chaput N; Mateus C; Grohmann U; Caillat-Zucman S; Zitvogel L; Robert C
Clin Cancer Res; 2008 Aug; 14(16):5242-9. PubMed ID: 18698043
[TBL] [Abstract][Full Text] [Related]
18. Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors.
Arce Vargas F; Furness AJS; Solomon I; Joshi K; Mekkaoui L; Lesko MH; Miranda Rota E; Dahan R; Georgiou A; Sledzinska A; Ben Aissa A; Franz D; Werner Sunderland M; Wong YNS; Henry JY; O'Brien T; Nicol D; Challacombe B; Beers SA; ; ; ; Turajlic S; Gore M; Larkin J; Swanton C; Chester KA; Pule M; Ravetch JV; Marafioti T; Peggs KS; Quezada SA
Immunity; 2017 Apr; 46(4):577-586. PubMed ID: 28410988
[TBL] [Abstract][Full Text] [Related]
19. Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization.
Rausch J; Lopez PA; Bialojan A; Denny M; Langguth P; Probst HC; Schild H; Radsak MP
J Dermatol Sci; 2017 Sep; 87(3):300-306. PubMed ID: 28666747
[TBL] [Abstract][Full Text] [Related]
20. XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer.
Jenkins KA; Park M; Pederzoli-Ribeil M; Eskiocak U; Johnson P; Guzman W; McLaughlin M; Moore-Lai D; O'Toole C; Liu Z; Nicholson B; Flesch V; Qiu H; Clackson T; O'Hagan RC; Rodeck U; Karow M; O'Neil J; Williams JC
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38164757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
